|
1
|
Valdes-Balbin Y, Santana-Mederos D, Paquet F, Fernandez S, Climent Y, Chiodo F, Rodríguez L, Sanchez Ramirez B, Leon K, Hernandez T, Castellanos-Serra L, Garrido R, Chen GW, Garcia-Rivera D, Rivera DG, Verez-Bencomo V. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. ACS CENTRAL SCIENCE 2021; 7:757-767. [PMID: 34075345 PMCID: PMC8084267 DOI: 10.1021/acscentsci.1c00216] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Indexed: 02/08/2023]
Abstract
The development of recombinant COVID-19 vaccines has resulted from scientific progress made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer, its trimer, and its recombinant receptor-binding domain (RBD) induce a potent anti-RBD neutralizing antibody response in animals. In COVID-19 convalescent sera, there is a good correlation between the antibody response and potent neutralization. In this review, we summarize with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof. Recent trends in RBD-based vaccines are analyzed, providing detailed insights into the role of antigen display and multivalence in the immune response of vaccines under development.
Collapse
Affiliation(s)
| | | | - Françoise Paquet
- Centre
de Biophysique Moléculaire, Centre
National de la Recherche Scientifique UPR 4301, rue Charles Sadron, F-45071, Orléans, Cedex 2, France
| | | | - Yanet Climent
- Finlay
Vaccine Institute, 200
and 21 Street, Havana 11600, Cuba
| | - Fabrizio Chiodo
- Department
of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, 1081 HV
- Institute
of Biomolecular Chemistry, National Research
Council (CNR), Pozzuoli, Napoli, Italy
| | - Laura Rodríguez
- Finlay
Vaccine Institute, 200
and 21 Street, Havana 11600, Cuba
| | | | - Kalet Leon
- Center
of Molecular Immunology, P.O. Box 16040, 216 Street, Havana, Cuba
| | - Tays Hernandez
- Center
of Molecular Immunology, P.O. Box 16040, 216 Street, Havana, Cuba
| | | | - Raine Garrido
- Finlay
Vaccine Institute, 200
and 21 Street, Havana 11600, Cuba
| | - Guang-Wu Chen
- Chengdu
Olisynn Biotech. Co. Ltd. and State Key Laboratory of Biotherapy and
Cancer Center, West China Hospital, Sichuan
University, Chengdu 610041, People’s Republic of China
| | | | - Daniel G. Rivera
- Laboratory
of Synthetic and Biomolecular Chemistry, Faculty of Chemistry, University of Havana, Zapata & G, Havana 10400, Cuba
| | | |
Collapse
|